MEDIFAST INC Annual Report - A Strategic Pivot and Performance Review

This summary provides investors with a clear, concise overview of MEDIFAST INC's annual report for the fiscal year ended December 31, 2025, highlighting the company's performance, strategic shifts, and key risks.

Business Overview MEDIFAST embarks on a significant strategic pivot, moving beyond traditional structured weight loss programs to target the broader "metabolic health market." This strategic shift aims to address the underlying causes of metabolic issues, not just the symptoms, positioning the company for long-term growth in an estimated $50 billion market segment. The company's core business model involves developing and distributing health and wellness products, primarily through an independent coach network.

This evolving strategy includes:

• Launching innovative product lines focused on areas like blood sugar management, gut health, and personalized nutrition.
• Enhancing their independent coach network with specialized training in metabolic health.
• Investing in AI-driven tools for personalized coaching, data analytics, and improved customer engagement.

Fiscal Year 2025 Performance Highlights:

MEDIFAST experienced a challenging yet transformative year.

• Revenue: Total revenue for 2025 declined 18% to $900 million, down from $1.1 billion in the prior year. This decline reflects competitive pressures and the initial impacts of their strategic transition.
• Profitability: Net income decreased 50% to $50 million, or $4.50 per diluted share, compared to $100 million ($9.00 per diluted share) in 2024. Increased investments in research and development (R&D) and marketing for new initiatives related to the strategic pivot partly contributed to this reduction.

Financial Health Despite reduced profitability, the company maintained a strong financial position.

• Cash Flow: MEDIFAST generated $75 million in operating cash flow during 2025.
• Balance Sheet: The company ended the year with a healthy $150 million in cash and equivalents and manageable total debt of $50 million. This indicates strong liquidity and a solid financial foundation to support its strategic investments.

Management Discussion (MD&A Highlights) Fiscal year 2025 featured a bold strategic shift towards embracing the metabolic health market. This pivot directly responds to evolving market dynamics and consumer needs. The decline in revenue and profitability reflects both competitive pressures and the initial investment phase of this transition, including increased spending in R&D, technology, and marketing.

MEDIFAST plans to invest approximately $75 million in R&D, technology, and marketing over the next two years to accelerate this transition. Management believes this strategic reorientation, focusing on a holistic, coach-guided approach to metabolic health, is crucial for long-term sustainable growth and market relevance. The independent coach network's evolution to provide specialized training is central to delivering this new value proposition.

Competitive Position The health and wellness market is highly competitive and rapidly evolving. MEDIFAST faces significant competition from various fronts, including the rapid rise of GLP-1 weight-loss medications (like Ozempic and Wegovy), which directly challenge traditional weight management approaches. Additionally, new entrants and competitors leveraging AI and advanced technology are intensifying market competition.

MEDIFAST's competitive strategy differentiates the company by pivoting to the broader metabolic health market, offering a holistic, coach-guided approach that addresses underlying health issues rather than just symptoms. The company supports this strategy through:

• New product development in areas like blood sugar management and gut health.
• An enhanced coaching model with specialized training.
• Significant investment in AI-driven tools for personalized client engagement.

MEDIFAST aims to leverage its established coach network and expertise to provide a more comprehensive and personalized solution compared to pharmaceutical or purely digital competitors.

Key Risks and Challenges:

Investors should be aware of several material risks that could impact MEDIFAST's future performance:

• Strategic Execution: Successfully implementing the ambitious pivot to metabolic health is a major undertaking. Failure to effectively develop new products, retrain coaches, or gain market acceptance could hinder growth and investment returns.
• Intense Competition: The health and wellness market is highly competitive. The rapid rise of GLP-1 weight-loss medications (like Ozempic and Wegovy) presents a significant challenge, requiring MEDIFAST to clearly differentiate its holistic, coach-guided approach. New entrants and competitors leveraging AI also pose a threat.
• Coach Network Reliance: MEDIFAST's business model heavily relies on its independent coach network. The ability to attract, retain, and effectively train coaches, especially with the new strategic focus, is crucial. The active coach count saw a slight decline in 2025, making retention a key priority.
• Product Innovation & Marketing: Continuous innovation in products and effective marketing strategies are essential to stay relevant and attract new customers in a dynamic market.
• Regulatory & Legal Landscape: Changes in health regulations, product liability claims, or evolving advertising standards could impact operations and profitability.
• Supply Chain & Operations: Potential disruptions in the global supply chain could affect product availability and costs.
• Economic Conditions: General economic downturns or shifts in consumer spending habits could reduce demand for health and wellness products.

Future Outlook MEDIFAST anticipates 2026 will be a year of continued investment and transition as the company executes its strategic pivot to metabolic health. While the company expects revenue stabilization, initial returns on its metabolic health investments should become more evident in the latter half of the year, laying the groundwork for renewed growth. The company will continue to focus on product innovation, coach network development, and technology integration to solidify its position in the evolving health and wellness landscape.

Company Snapshot (as of February 10, 2026):

• Shares Outstanding: The company had 10,991,273 shares of common stock.
• Public Float: As of June 30, 2025, the public float stood at approximately $145.0 million, based on a stock price of $14.05 per share.
• Market Capitalization: Based on shares outstanding and recent stock prices, MEDIFAST's total market value is approximately $155 million.